has been cited by the following article(s):
[1]
|
Safety profiles of adalimumab, etanercept and infliximab: a pharmacovigilance study using a measure of disproportionality in a database of spontaneously reported adverse events
Journal of Clinical Pharmacy and Therapeutics,
2014
DOI:10.1111/jcpt.12148
|
|
|